Related Experiment Video
Updated: Feb 18, 2026

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
Published on: June 29, 2013
Critical limb ischemia update and the evolving role of drug-elution technologies
Jared B Hooker1, Beau M Hawkins1
1a Cardiovascular Diseases Section, Department of Internal Medicine , University of Oklahoma Health Sciences Center , Oklahoma City , OK , USA.
Insights
Critical limb ischemia (CLI) treatment advances include drug-eluting therapies. Drug-eluting stents (DES) and drug-coated balloons (DCB) are key for femoropopliteal disease, while angioplasty is standard for below-knee lesions.
Area of Science:
- Vascular Surgery
- Interventional Cardiology
- Endovascular Therapies
Background:
- Critical limb ischemia (CLI) presents significant cardiovascular mortality and amputation risks.
- Effective management strategies for CLI are crucial for patient outcomes.
- Reviewing current epidemiological data and treatment modalities is essential.
Purpose of the Study:
- To review the epidemiology of critical limb ischemia.
- To discuss current revascularization options for CLI.
- To evaluate the role of drug-elution therapies in CLI management.
Main Methods:
- Literature review of epidemiological studies on CLI.
- Analysis of revascularization techniques, including surgical and endovascular approaches.
- Assessment of drug-eluting stents (DES) and drug-coated balloons (DCB) efficacy.
Main Results:
- Drug-eluting stents (DES) and drug-coated balloons (DCB) demonstrate improved patency in the femoropopliteal segment.
- These drug-elution therapies are often considered first-line treatments for femoropopliteal disease.
- For below-knee disease, angioplasty remains the primary strategy, with DES utilized for focal lesions to mitigate restenosis.
Conclusions:
- Drug-elution therapies offer significant benefits for femoropopliteal critical limb ischemia.
- Treatment decisions for CLI should be tailored to lesion location and characteristics.
- Further research may refine the role of DES and DCB in complex CLI cases.
Introduction:
Critical limb ischemia (CLI) is a prevalent condition associated with cardiovascular mortality and limb loss. Areas covered: This review discusses the epidemiology of CLI, revascularization options, and drug-elution therapies. Expert commentary: Drug-eluting stents (DES) and drug-coated balloons (DCB) improve patency rates in the femoropopliteal segment, and are generally used as first-line therapies. For below-knee disease, angioplasty is the default strategy unless lesions are focal whereby DES can be used to reduce restenosis risk.
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Peripheral Artery Disease V: Postoperative Nursing Management
Peripheral Artery Disease IV: Nursing Management
Peripheral Artery Disease I: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

